13F Holdings
中文EN

IBIO iBio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420720 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY115.0%
TTM net income YoY-73.4%
TTM EPS YoY81.4%
Revenue 3-yr CAGR178.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,491.0%
Net margin-3,244.2%
FCF margin-2,566.3%
EBITDA margin-3,437.0%

Returns

ROE-51.8%
ROA-45.6%
ROIC (approx.)-97.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue60.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$100,000$400,000$225,000$0$1.88M
Cost of revenue————$216,000
Gross profit————$2.17M
R&D expense$19.64M$8.31M$5.18M$10.33M$9.83M
SG&A expense$10.60M$10.69M$11.67M$19.02M$21.75M
Operating income-$35.14M-$18.60M-$16.63M-$29.34M-$29.70M
Interest expense$53,000$212,000$172,000$83,000$1.41M
Pretax income-$33.04M-$18.38M———
Income tax$0$0$0$0$0
Net income-$33.04M-$18.38M-$24.91M-$65.01M-$50.30M
EBITDA-$34.58M-$18.12M-$16.00M-$28.67M-$27.42M
EPS (basic)-0.32-1.75-6.50-106.19-5.78
EPS (diluted)-0.32-1.75-6.50-106.19-5.78
Weighted avg. shares (diluted)104.06M10.50M3.83M612,0008.72M
Balance sheet
Cash & equivalents$56.40M$8.79M$14.43M$7.58M$28.67M
Short-term investments$31.64M$0$0——
Receivables—$0$0$0$1.00M
Inventory——$0$0$3.90M
Current assets$92.22M$9.72M$15.67M$26.26M$45.07M
PP&E, net$3.09M$3.16M$3.63M$4.22M$1.37M
Intangibles$1.82M$6.85M$5.37M$5.39M$4.85M
Total assets$99.11M$23.18M$28.73M$41.21M$99.41M
Current liabilities$11.74M$6.11M$3.84M$22.11M$30.44M
Total liabilities$13.40M$8.30M$7.41M$25.83M$35.92M
Shareholders' equity$85.71M$14.88M$21.32M$15.38M$63.48M
Shares outstanding55.70M19.35M8.62M1.02M8.73M
Cash flow statement
Operating cash flow-$23.22M-$15.30M-$18.55M-$30.44M-$37.48M
Capital expenditure$578,000$16,000$210,000$5.74M$7.33M
Free cash flow-$23.80M-$15.32M-$18.76M-$36.17M-$44.81M
Investing cash flow-$32.00M$742,000$906,000$7.01M-$5.13M
Financing cash flow$103.05M$8.93M$24.49M$2.30M-$6.12M
Depreciation & amortization$558,000$484,000$638,000$674,000$2.27M
Stock-based compensation$1.37M$1.53M$2.04M$4.39M$4.38M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.